In this study, bovine serum albumin (BSA) hollow-nano-spheres (HNS) were synthesized as nano-carriers for paclitaxel (PTX) as model drug. Hierarchically, first, the exterior surface of silica nanoparticles was modified with (3-aminopropyl)triethoxysilane (APTES) and then with glutaraldehyde (GA). Then, BSA at alkaline pH was adsorbed on the surface of the modified nanoparticles and further crosslinked with GA. Finally, the core was acid washed to obtain HNS. The results indicated that the HNS is successfully formed with a spherical structure and an average shell thickness of 8 nm and a diameter of 28 nm. Subsequently, different ratios of PTX-HNS were used for in vitro release study of PTX. The opted amount of PTX-HNS was 10% and the release data were more compatible with the Gallagher-Corrigan model. The in vitro cytotoxicity activity of the PTX-loaded HNS was assessed using lung cancer cell lines. According to the MTT assay for 24 and 48 h period, the cell survival rate reduction of the incubated cells with the PTX-HNS of 0.1, 1, and 10 μg mL⁻¹ doses after 48 h was remarkably higher than that of the pure drug. The present study could represent a further step towards a rational colloidal hollow-nanocarrier design, preparation, and usage.

在这项研究中，牛血清白蛋白（BSA）空心纳米球（HNS）被合成为紫杉醇（PTX）的纳米载体作为模型药物。从层次上讲，首先用（3-氨基丙基）三乙氧基硅烷（APTES）然后用戊二醛（GA）修饰二氧化硅纳米颗粒的外表面。然后，将碱性pH下的BSA吸附在改性纳米颗粒的表面上，并进一步与GA交联。最后，将芯酸洗以获得HNS。结果表明，HNS成功地形成为球形结构，平均壳厚度为8nm，直径为28nm。随后，将不同比例的PTX-HNS用于PTX的体外释放研究。PTX-HNS的选择量为10％，且释放数据与Gallagher-Corrigan模型更兼容。使用肺癌细胞系评估了PTX加载的HNS的体外细胞毒性活性。根据MTT分析24和48小时，PTX-HNS分别为0.1、1和10μgmL的培养细胞的细胞存活率降低48小时后的^-1剂量显着高于纯药物的剂量。本研究可能代表朝着合理的胶体空心纳米载体设计，制备和使用迈出的又一步。